Efficacy of Cytoflavin in patients with multiple sclerosis and fatigue
Comparison in people · 2015
- What was studied
- 62 screened; 53 with fatigue allocated to Cytoflavin (20) or conventional therapy (33)
- Main finding
- The Cytoflavin group’s MFIS score fell from 45.1±4.5 to 29±4.2 (reported within-group p<0.05). The comparator regimen included pentoxifylline, piracetam, meldonium and B vitamins. The result cannot be attributed to either piracetam or meldonium.
Study data at a glance
- Participants or experimental model
- 62 screened; 53 with fatigue allocated to Cytoflavin (20) or conventional therapy (33)
- Reported results
- The Cytoflavin group’s MFIS score fell from 45.1±4.5 to 29±4.2 (reported within-group p<0.05). The comparator regimen included pentoxifylline, piracetam, meldonium and B vitamins. The result cannot be attributed to either piracetam or meldonium.
Study limitations and source details
Study limitations
- Unequal groups; randomization and blinding are not established.
- 62 is the screened population, not the number allocated to treatment groups.
- A within-group change is not a demonstrated between-group effect; fatigue improvement is not disease modification.
Source details
Publisher full text
The summary reflects the results reported in the cited source.
Methods and results reviewed
Sources checked
Citation
O. A. Mialovitska. Efficacy of Cytoflavin in patients with multiple sclerosis and fatigue Ukrainian Medical Journal. Published 18 March 2015